ErbB2 is frequently highly expressed in premalignant breast cancers, including ductal carcinoma in situ (DCIS); however, little is known about the signals or pathways it contributes to progression into the invasive/malignant state. Radiotherapy is often used to treat early premalignant lesions regardless of ErbB2 status. Here, we show that clinically relevant doses of ionizing radiation (IR)-induce cellular invasion of ErbB2-expressing breast cancer cells, as well as MCF10A cells overexpressing ErbB2. ErbB2-negative breast cancer cells, such as MCF7 and T47D, do not invade following treatment with IR nor do MCF10A cells overexpressing epidermal growth factor receptor. ErbB2 becomes phosphorylated at tyrosine 877 in a dose-and time-dependent manner following exposure to X-rays, and activates downstream signaling cascades including PI3K/Akt. Inhibition of these pathways, as well as inhibition of reactive oxygen species (ROS) with antioxidants, prevents IR-induced invasion. Activation of ErbB2-dependent signaling results in upregulation of the forkhead family transcription factor, FoxM1, and its transcriptional targets, including matrix metalloproteinase 2 (MMP2). Inhibition of FoxM1 by RNA interference prevented induction of invasion by IR, and overexpression of FoxM1 in MCF10A cells was sufficient to promote IR-induced invasion. Moreover, we found that 14-3-3z is also upregulated by IR in cancer cells in a ROS-dependent manner, is required for IR-induced invasion in ErbB2-positive breast cancer cells and together with FoxM1 is sufficient for invasion in ErbB2-negative breast cancer cells. Thus, our data show that IR-mediated activation of ErbB2 and induction of 14-3-3z collaborate to regulate FoxM1 and promote invasion of breast cancer cells and furthermore, may serve as therapeutic targets to enhance radiosensitivity of breast cancers.
INTRODUCTION
The human epidermal growth factor receptor family of transmembrane receptor tyrosine kinases comprises four members (epidermal growth factor receptor, (EGFR), ErbB2, ErbB3 and ErbB4), whose overexpression during carcinogenic progression is well-established. 1, 2 Receptor activation via homo or heterodimerization initiates signaling cascades involved in proliferation, apoptotic inhibition, migration and invasion. 3 Clinically, overexpression of the second member, HER2/neu (ErbB2), in malignant breast cancer is associated with aggressive tumors, drug resistance and poor prognosis. 2 ErbB2 is frequently overexpressed in ductal carcinoma in situ (DCIS), 1, 4 a premalignant breast lesion that can progress to malignancy. The factors and signaling involved in promoting transition from an ErbB2-positive, non-invasive DCIS lesion to invasive ductal carcinoma are poorly understood.
ErbB2, unlike its sister receptors, does not have a known ligand and may not be capable of binding ligand. 5 Nonetheless, it is an important heterodimeric partner for EGFR and ErbB3 in driving downstream signaling. 6 Interestingly, all human epidermal growth factor receptor family members, which normally require ligand binding for activation, can become phosphorylated in response to ionizing radiation (IR) independent of ligand binding. [7] [8] [9] [10] Furthermore, exposure to IR and other oxidative stressors has been shown to promote invasion and increase tumorigenicity, even in nonmalignant mammary epithelial cells. [11] [12] [13] A mechanism underlying radiogenic activation of ErbB2 and its effect on development of an invasive phenotype has yet to be examined.
A number of recent studies have implicated FoxM1, a member of the Forkhead family of transcription factors, as being a key regulator of cancer progression. FoxM1 has been shown to be overexpressed in a number of cancers 14, 15 and its expression, which is associated with poor prognosis, 16 correlates with ErbB2 overexpression in breast cancer cell lines and tissue samples. 17 In addition, elevated FoxM1 is correlated with resistance to chemotherapeutic agents and Herceptin. 18 FoxM1 can induce expression of a number genes associated with oncogenesis. 19 A mechanism linking ErbB2 and FoxM1 in promoting invasion has yet to be established.
The regulatory protein 14-3-3z is frequently expressed in early stage tumors and its expression in later stages is associated with a poor prognosis, 20 and has also been implicated in ErbB2-mediated invasion in breast cancer cells. 21 Similar to ErbB2, 14-3-3z overexpression can confer luminal filling in vitro, 22 but does not lead to invasion. Specific mechanisms for its cooperation with ErbB2 are poorly characterized. Although 14-3-3z is upregulated in many cancer cells, it is unclear what carcinogenic pathways can induce 14-3-3z levels, and which 14-3-3z targets are important to carcinogenic progression.
To study whether IR affects ErbB2 signaling and tumor progression, we used three dimensional (3D) cell culture to model physiologically relevant cellular and matrix interactions and signaling. [23] [24] [25] Culture of the immortalized human mammary epithelial cell line, MCF10A, in reconstituted basement membrane (for example, Matrigel) leads to the formation of polarized, hollow, acinar-like structures, with properties similar to normal mammary ducts; transduction of MCF10A cells with ErbB2 results in the generation of disorganized, filled, DCIS-like structures that remain non-invasive when cultured in reconstituted basement membrane. 25, 26 Here, we demonstrate that treatment of ErbB2-expressing breast epithelial cells with a single dose of 2 Gy X-rays induces ErbB2 phosphorylation, downstream signaling and invasion of 3D structures. IR-induced invasion is mediated through a Src and PI3K/Akt-dependent mechanism that leads to increased levels of FoxM1. Inhibition of ErbB2, Src, Akt or FoxM1 prevents IR-mediated invasion. In addition, we find that 14-3-3z expression is elevated following IR-treatment and is required for invasion. Pretreatment with antioxidants abolishes ErbB2 phosphorylation and FoxM1 upregulation in response to IR, suggesting oxidative stress is important for this effect. Thus, coexpression of ErbB2, FoxM1 and 14-3-3z may be indicative of DCIS lesions that are more likely to be refractory to radiation treatment and potentially progress to malignancy.
RESULTS

IR induces invasion in ErbB2-expressing breast cells
It has been previously reported that EGFR, a heterodimer partner of ErbB2, becomes phosphorylated in response to IR. 7 To examine the response of ErbB2 to IR, we performed a dose-response experiment with MCF10A cells transduced to express wild-type ErbB2 (MCF10A-ErbB2). Western blotting for phosphorylated ErbB2 (Y877) showed increasing ErbB2 activation with increasing dose, from 0.5-5.0 Gy X-rays (Figure 1a) . Subsequent experiments were performed using a dose of 2 Gy due to its clinical relevance, as 2 Gy is frequently used in a single fraction of radiotherapy to the breast. 27 To examine the effects of IR and increased ErbB2 activation, we cultured MCF10A cells and MCF10A-ErbB2 in 3D Matrigel culture to allow the cells to form 3D structures. Control MCF10A cells formed acini comprising a hollow lumen surrounded by a single layer of polarized epithelial cells with basal deposition of laminin V and actin localization predominantly at cell À cell junctions (Figure 1b) as previously described. 26 MCF10A-ErbB2 cells formed hyperproliferative, disorganized, filled structures that were non-invasive and maintained localization of basal markers, such as laminin V (Figure 1b ) and integrin a6 (Supplementary Figure 1A) . 25, 26 After 1 week of 3D culture, structures were treated with 2 Gy X-rays and monitored by light microscopy for 10 days. Control, unirradiated MCF10A-ErbB2 structures remained filled, Figure 1B) . In contrast, no invasive projections or changes in basal markers were evident in MCF10A cells treated with IR throughout culture period (Figure 1b) . By 3 weeks postirradiation, 100% of MCF10A-ErbB2 structures became invasive (data not shown). This phenotype was maintained even after dispersion of structures with EDTA and reseeding of cells in Matrigel (Supplementary Figure 1C) , suggesting stability of the invasive phenotype.
To further investigate the requirement for ErbB2 expression in promoting IR-induced invasion, we performed a similar experiment with a panel of ErbB2-positive (SKBR3, BT-474) and ErbB2-negative (MCF7, T47D) breast cancer cell lines (Figure 1b) . Consistent with the above results, ErbB2-expressing BT-474 and SKBR3 cells, which are inherently non-invasive when cultured in 3D, 28 became invasive in response to IR, while MCF7 and T47D cells showed no changes in morphology or laminin localization (Figure 1b) .
To quantify IR-mediated invasion of ErbB2-expressing cells, we used transwell invasion assays. Cells were seeded in tranwell invasion chambers overnight, then irradiated and allowed to invade for 24 h and the relative invasion (treated versus untreated) was determined for each condition. MCF10A-ErbB2 cells had a 5.33-fold increase in invasion following IR compared with MCF10A cells (Figure 1c ). Consistent with 3D culture experiments, MCF7 and T47D cells showed no significant changes in invasiveness following irradiation in invasion chambers; however, SKBR3 and BT-474 cells showed significantly increased invasion following irradiation ( Figure 1c ). This effect was specific to ErbB2 expression, as there was no change in invasion upon irradiation of MCF10A cells overexpressing EGFR (Figure 1d) . Thus, these results show that a clinically relevant dose of IR stimulates ErbB2 phosphorylation and induces invasion in ErbB2-expressing breast cancer cells.
Reactive oxygen species are involved in IR-mediated ErbB2 activation and invasion It is well-established that reactive oxygen species (ROS) have an important role in mediating the effects of IR. 29 ROS can be generated both extracellularly via ionization of water or other components of media or intracellularly via metabolic changes or damage to mitochondria. 30 The signaling capabilities of ROS, particularly for metabolic, survival and migratory functions have been well-studied in other systems. 13 To investigate a possible role for ROS in IR-mediated ErbB2 activation, we pre-treated MCF10A-ErbB2 cells cultured in 2% Matrigel medium with the ROS scavenger N-acetylcysteine (NAC) or Trolox. 
IR-induced invasion requires activation of PI3K-AKT signaling
We next sought to investigate, which downstream pathway was activated in response to activation of ErbB2 by IR. Both MAPK/ERK and PI3K/AKT pathways are known to be activated downstream of ErbB2 phosphorylation. Western blot analysis of irradiated MCF10A-ErbB2 cells showed strong activation of Akt signaling for up to 24 h, but only a modest increase in phosphorylated Erk, which decreased by 24 h (Figure 4a) . Similar results were obtained in the breast cancer cell line, SKBR3 (Supplementary Figure 3A) . Inhibition of PI3K with LY294002 reduced relative invasion 4.9-fold Ninety minutes before irradiation (2 Gy), they were treated with 5 mM UO126 or 50 mM LY294002. Invasion was quantitated 24 h postirradiation (*P ¼ 0.003, **P ¼ 0.036, ***P ¼ 0.002, mean ± s.e.m.). (c) MCF10A-ErbB2 cells were grown in 3D for 7 days then treated with UO126 or LY294002 90 min before IR. Representative structures were imaged on Day 10 postirradiation. Red: laminin; Green: Phalloidin; Blue: DAPI.
ErbB2, FoxM1, and 14-3-3z prime cells for invasion DM Kambach et al compared with dimethylsulphoxide treatment as measured by transwell invasion assay, significantly more than the MEK inhibitor U0126, which reduced relative invasion 1.6-fold (Figure 4b ). This selective effect for PI3K inhibitors was strongly seen in 3D culture. Compared with dimethylsulphoxide-treated irradiated MCF10A-ErbB2 with 45.1% invasive structures, only 3.24% of irradiated LY294002 treated structures became invasive, as compared with 25.2% of irradiated U0126-treated structures (Figure 4c ). Supportive of the requirement for PI3K signaling in driving invasion, a PI3K-activating peptide was able to significantly increase invasion of MCF10A-ErbB2 cells 2.35-fold more than control peptide independent of IR (Supplementary Figure 3B) . Thus, PI3K/Akt is a critical pathway activated by IR-induced ErbB2 phosphorylation that promotes invasion.
Upregulation of FoxM1 is required for IR-induced invasion As the forkhead family transcription factor FoxM1 has been identified as a key mediator of oxidative stress 37 and a downstream target of ErbB2 signaling, 17 we next investigated whether FoxM1 signaling might contribute to IR-induced invasion.
Indeed, FoxM1 protein levels increase in response to irradiation of MCF10A-ErbB2 (Figure 5a ) and SKBR3 cells (Supplementary Figure 3A) . Increased in FoxM1 protein levels by IR was independent of changes in FoxM1 RNA, as we did not detect any increase in FoxM1 RNA levels in IR-treated MCF10A-ErbB2 or SKBR3 cells (Supplementary Figure 3C) . Induction of FoxM1 was dependent on ErbB2 and c-Src activation as pre-treatment with Lapatinib (Figure 5b ), AG1478 or PP2 (Supplementary Figure 4A) abolished the increase in FoxM1 following irradiation of MCF10A-ErbB2 cells. In addition, NAC pre-treatment also significantly reduced FoxM1 induction by IR (Supplementary Figure 4B) .
To determine the specific role for FoxM1 downstream from ErbB2 in IR-induced invasion, we initially examined expression of transcriptional targets of FoxM1 in response to IR. Survivin, PLK1 and matrix metalloproteinase 2 (MMP2) all increased in response to IR (Supplementary Figure 4C) ; however, only MMP2 production was maintained for at least 24 h at both the protein and mRNA levels (Supplementary Figures 4C, D) . MMP2 is a zinc-dependent endopeptidase with a well-established role in breast cancer development and pathological matrix remodeling 38, 39 and a known target of FoxM1. 40, 41 MMP2 mRNA levels, as assessed by Figure 4D) , suggesting that IR-induced invasion is associated with upregulation of MMP2.
To test the requirement of FoxM1 for IR-mediated invasion, we targeted FoxM1 with RNA interference. Knockdown of FoxM1 in MCF10A-ErbB2 cells with two independent small hairpin RNA (shRNA) sequences (inset, Figure 5c ) abolished invasion both in transwell chambers (Figure 5c ) and 3D culture (Figure 5d ). Thus, FoxM1 is required for the induction of invasion by ErbB2-positive cells in response to IR. To determine whether FoxM1 upregulation is sufficient to promote invasion, FoxM1 was overexpressed in MCF10A cells (Figure 5e, inset) . Without irradiation, overexpression of FoxM1 in MCF-10A cells had no effect on invasion in 3D (Figure 5f ) or transwell invasion assays (data not shown). However, irradiation significantly increased relative invasion through transwell chambers (Figure 5e ) and in 3D culture (Figure 5f ) Results with MCF10A-FoxM1 cells suggest that expression of FoxM1 in the absence of ErbB2 is capable of driving IR-induced invasion. Thus, we concluded that while ErbB2 is important for upregulation of FoxM1 in response to IR, high levels of FoxM1 is sufficient to promote IR-induced invasion.
14-3-3z is induced by IR in breast cancer cells Having shown that ErbB2 and FoxM1 expression is required for invasion, we investigated whether overexpression of ErbB2 in
ErbB2-negative breast cancer cells MCF7 and T47D would be sufficient to drive invasion in response to IR. Interestingly, while MCF7-ErbB2 cells became invasive following IR treatment, T47D-ErbB2 cells did not (Figure 6a ), despite ErbB2 activation in both (Figures 6b and c) . Although parental MCF7 cells express little FoxM1 compared with other breast cancer cells (Figure 6d ), stable expression of ErbB2 in these cells conferred IR-mediated induction of FoxM1 (Supplementary Figure 5) . Surprisingly, T47D cells express a high basal level of FoxM1 (Figure 6d ) yet, they did not become invasive following stable expression of ErbB2 and IR treatment (Figure 6a) . Thus, while ErbB2 and FoxM1 may be necessary for IR-mediated invasion, we reasoned that an additional regulatory factor(s) may be required for IR-mediated invasion.
Coexpression of the regulatory protein 14-3-3z with ErbB2 was previously shown to promote DCIS progression to an invasive lesion, 21 and recently has been shown to have an upstream regulatory function on FoxM1. 42 We investigated whether 14-3-3z expression was predictive, of which cell lines became invasive. All three of the ErbB2-positive cell lines expressed 14-3-3z (Figure 6d) . Moreover, irradiation of MCF10A-ErbB2 cells increased 14-3-3z protein levels (Figure 6e ), and preincubation of these cells with NAC reduced induction of 14-3-3z (Figure 6f ).
14-3-3z levels were similarly increased in both ErbB2-positive and ErbB2-negative breast cancer cell lines in response to IR (Supplemental Figure 6 ), suggesting that 14-3-3z protein induction by IR can occur independent of ErbB2 expression. Indeed, Figure 4A) . However, 14-3-3z induction by IR was c-Src dependent, as PP2 treatment of MCF10A-ErbB2 cells blocked this increase (Supplementary Figure 4A) . Of the breast cancer cell lines, T47D had the lowest levels of 14-3-3z ( Figure 6d ) and 14-3-3z expression was not induced in these cells following irradiation (Supplementary Figure 6E) nor in T47D cells expressing ErbB2 (data not shown), suggesting 14-3-3z may be an additional factor required for IR-mediated invasion.
14-3-3z is required for ErbB2/FoxM1 IR-mediated invasion To determine the requirement of 14-3-3z in promoting IR-induced invasion of ErbB2-positive cells, we knocked down 14-3-3z expression using two independent shRNA sequences. Inhibition of 14-3-3z prevented invasion of MCF10A-ErbB2 cells in response to IR, in both transwell invasion assays (Figure 7a ) and 3D culture (Figure 7b) . Thus, 14-3-3z is required for IR-induced invasion.
We hypothesized that 14-3-3z might be a missing factor in T47D cells precluding them from invading in the presence of high levels of FoxM1. To test this, we overexpressed 14-3-3z in T47D cells. T47D-14-3-3z cells were 2.55-fold more invasive than T47D-control cells (Figure 7c ). Furthermore, T47D-14-3-3z cells expressed higher levels of FoxM1 and its target MMP2 compared with T47D control cells (Figure 7d ). From these data we concluded that IR-mediated induction of 14-3-3z is an additional event required for the invasion of FoxM1-positive cells and can bypass the need for ErbB2. Thus, we show for the first time that oxidative stress mediated by IR can increase phosphorylation of ErbB2, via Src, leading to increased expression of FoxM1 and its transcriptional target MMP2. In parallel, the regulatory protein 14-3-3z is upregulated by oxidative stress and Src independent of ErbB2, and is required to promote invasion of FoxM1-expressing cells. Cooperation between these pathways can drive non-invasive DCIS-like structures to become invasive.
DISCUSSION
The processes that govern the transition from premalignant DCIS to invasive breast cancer are poorly understood, and currently there are no known markers to distinguish DCIS that is likely to progress to malignancy from DCIS that would be unlikely to invade if left untreated. As a result, most patients currently receive the same therapeutic regimen. Our results identify for the first time that cells coexpressing ErbB2, 14-3-3z and FoxM1 become invasive in response to IR. Though each has previously been identified as having a role in invasion and/or metastasis, 2, [19] [20] [21] 41 none alone is sufficient to drive invasion of epithelial cells. As evidenced by our results, expression of all three may increase the invasive potential of premalignant cells and may drive progression to malignancy in response to IR or increased oxidative stress.
Coexpression of 14-3-3z and ErbB2 has previously been associated with the presence of microinvasion in the clinical samples of DCIS, as well as with higher rates of recurrence and death in inflammatory breast cancer. 21 Overexpression of ErbB2 and 14-3-3z together in MCF-10A cells has previously been shown to increase invasion in 3D culture via an ErbB2/Src-mediated increase in motility and 14-3-3z-mediated activation of TGFb-SMAD signaling. 21 Our data, for the first time, identify increased oxidative stress as a physiological mechanism, by which 14-3-3z levels are increased in breast cancer cells. The regulation of 14-3-3z by ROS is independent of ErbB2 expression and activation, but dependent on Src activation; however, further mechanistic detail will require additional study. It is possible that, in addition to increased protein levels, ROS may regulate post-translational modification or localization of 14-3-3z, which may also be critical for its role in invasion.
In addition, our data suggest that mere expression of ErbB2, FoxM1 and 14-3-3z is not sufficient for invasion, but rather primes the cell for an invasive response to stress. Indeed, we show that breast cancer cells expressing these three markers become invasive during conditions of increased oxidative stress, such as conditions induced by IR. In addition, we show involvement of Src in promoting IR-induced invasion. ErbB2/Src signaling drives invasion in a PI3K/Akt-dependent manner, ultimately through upregulation of FoxM1 and its transcriptional targets, including MMP2. Furthermore, we have shown that oxidative stress is a key independent regulator of both ErbB2 and 14-3-3z, and these pathways may converge on FoxM1 to regulate invasion and cancer progression.
We and others have shown that ErbB2 is associated with increased FoxM1, 17 but as seen in Figure 5 , overexpression of FoxM1 alone is insufficient for invasion, alluding to the presence of an IR or ROS-mediated regulatory mechanism. Data with MCF10A-FoxM1 and T47D-14-3-3z cells indicate that high levels of FoxM1 and induction of 14-3-3z by IR can bypass the requirement for ErbB2 in IR-induced invasion, suggesting that 14-3-3z and elevated FoxM1 may be sufficient to prime cells for stress-induced invasion independent of ErbB2. Thus, our results may have additional implications for ErbB2-negative cancer cells that contain high levels of 14-3-3z and FoxM1. Indeed, both FoxM1 and 14-3-3z expression are associated with endocrine resistance in estrogen receptor positive breast cancers, [42] [43] [44] and are overexpressed in a variety of cancers 45, 46 including breast, lung, colon and pancreas. Recent evidence suggests that 14-3-3z is capable of regulating FoxM1 protein levels and FoxM1 specific targets including survivin and PLK1 in MCF-7 cells.
42 Because 14-3-3 family members lack innate catalytic activity and exert their regulatory functions largely through binding target ligands to inactivate them or alter their localization, 47, 48 we hypothesize that the regulatory activity of 14-3-3z on FoxM1 may be through the inhibition or sequestration of an inhibitor or competitor of FoxM1, 49, 50 allowing FoxM1 activity to increase under conditions of increased oxidative stress.
It is well-established that ROS are robust DNA damaging agents; however, mounting evidence suggests the contributions of oxidative stress to malignant progression are not solely limited to the induction of genomic instability. The contributions of cellular stress to carcinogenesis are the focus of ongoing investigation, and stress phenotypes are increasingly included amongst the traditional hallmarks of cancer. 51, 52 Our data indicate that oxidative stress activates ErbB2 signaling cascades and upregulates 14-3-3z levels. As both are important for regulation of FoxM1, 16, 17, 42 we propose that these pathways converge in response to ROS to drive malignant progression. This correlates with other reports, in which ROS inducing agents such as IR, chemotherapeutic agents or hypoxia are capable of increasing tumorigenicity. 12, 52 Many traditional cancer therapies rely upon the cytotoxic effects of ROS without consideration for the potent signaling capabilities of these radicals. ROS, particularly with respect to chemotherapy and radiation therapy, have been implicated in the induction and stabilization of tumor initiating cells, 52 which display the self-renewal properties and some markers of stem cells, and have roles in carcinogenesis and therapeutic resistance. ErbB2, likewise, has been associated with inducing expression of stem cell markers (even in normal mammary epithelial cells) and has a putative role in the initiation and maintenance of tumorinitiating cells subpopulations within a tumor. 53, 54 FoxM1 also has close ties with stem cell induction and maintenance, 55 and 14-3-3z has been implicated in epithelial-mesenchymal transition, 21 suggesting that the pathways described herein may regulate stem cell lineage and could be exploited in designing tumorinitiating cells-targeted therapies.
Understanding the mechanisms, by which oxidative stress can contribute to cancer progression or therapeutic resistance is crucial for identifying novel targets for adjuvant therapy to increase the efficacy of current treatment options. Our data suggest a novel stress mediated pathway regulating ErbB2 activity, and FoxM1 function that works in association with 14-3-3z to drive invasion. Thus, ErbB2, FoxM1 and 14-3-3z, may be an important set of markers for determining treatment strategy in DCIS patients, and furthermore that targeting 14-3-3z and/or the kinase activity of ErbB2 in conjunction with radiotherapy may further decrease the risk of malignant progression of DCIS.
MATERIALS AND METHODS
Cell culture
MCF10A cells and cells of MCF10A lineage (MCF10A-ErbB2, MCF10A-FoxM1) were cultured in Dulbecco's Modified Eagle Medium-F12 containing 5% horse serum (PAA, Pausching Austria), 20 mg/ml EGF (Peprotech, Rocky Hill, NJ, USA), 0.5 mg/ml hydrocortisone (Sigma-Aldrich, St Louis, MO, USA), 5 ng/ml cholera toxin (Sigma-Aldrich), 10 mg/ml insulin (SigmaAldrich), and 1% penicillin À streptomycin (Sigma-Aldrich). MCF7 cells and BT-474 cells were grown in Dulbecco's Modified Eagle Medium with 10% fetal bovine serum (FBS, Gemini Biosciences, West Sacramento, CA, USA), 10 mg/ml insulin and 1% penicillin À streptomycin. SKBR3 cells were grown in McCoys 5A containing 10% fetal bovine serum and 1% penicillin À streptomycin. T47D cells were grown in RPMI supplemented with 10% fetal bovine serum 10 mg/ml insulin and 1% penicillin À streptomycin. Three-dimensional Matrigel cultures utilized an overlay approach, as previously described. 25 A modified Matrigel cell culture method (2D.MG) was used to investigate cell signaling. Briefly, cells were resuspended in overlay medium (Dulbecco's Modified Eagle Medium-F12 containing 5% horse serum, 5 mg/ml EGF, 0.5 mg/ml hydrocortisone, 5 ng/ml cholera toxin, 10 mg/ml insulin, 1% penicillin À streptomycin and 2% Matrigel (BD Biosciences, San Jose, CA, USA)) and plated on tissue culture plastic 48 h before irradiation. These cells maintain cell À matrix interactions that are important for IRmediated ErbB2 phosphorylation and downstream signaling. The time course of IR-mediated ErbB2 activation was similar between 3D and 2D.MG samples (data not shown).
Retroviral vectors
Retroviral vectors for stable expression of pBabe-ErbB2 and pBabe-FoxM1 have been described previously. 15, 25 pBabe-HA-14-3-3z was constructed by cloning HA-14-3-3z complementary DNA insert from pcDNA3-HA-14-3-3z (kindly provided by Tim O'Toole, University of Louisville 56 ) to EcoRI and BamHI sites of pBabe-puro. RNA interference against FoxM1 and 14-3-3z was performed using two independent lentiviral pLKO.1-puromycin shRNA sequences each from The RNA interference Consortium (TRC) TRC-hs1.0 lentiviral shRNA library (FoxM1: Thermo Scientific, TRCN0000015543 and TRCN0000015544; 14-3-3z: Sigma-Aldrich, TRCN0000029404 and TRCN0000029405). A non-targeting pLKO.1-puromycin shRNA sequence was used as control (Sigma-Aldrich, catalog no. SHC002).
Irradiation, drug and inhibitor treatments
Cells were irradiated on a Siemens Primus linear accelerator with the generous assistance of the Radiation Oncology department at Drexel University College of Medicine. Cells were irradiated through 3 cm water equivalency plastic at an energy of 6 MV and a dose rate of 3 Gy/min. Doseresponse experiments were performed with each drug or inhibitor to determine the appropriate doses with, which to treat 3D MCF10A-ErbB2 cells to maintain viability. Optimal doses were determined to be 50 mM hydrogen peroxide (Calbiochem, La Jolla, CA, USA), 25 ng/ml neocarzinostatin (generously provided by the Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute), 4 mM N-acetyl cysteine (NAC; Sigma Aldrich), 1 mM AG1478 (Invitrogen, Carlsbad, CA, USA), 50 mM LY294002 (Calbiochem), 10 mM U0126 (Calbiochem), 5 mM PP2 (Biomol, Plymouth Meeting, PA, USA), 1 mM Lapatinib (Selleck Chemicals, Houston, TX, USA) and 50 nM Dasatinib (Selleck Chemicals). For inhibition studies, including ROS scavenger studies utilizing NAC, each drug was added to medium 1.5 h before irradiation. ErbB2, FoxM1, and 14-3-3z prime cells for invasion DM Kambach et al
Invasion assay
Cells were seeded in the BD Matrigel Invasion Inserts (BD Biosciences) for 24 h before irradiation in medium lacking EGF. Immediately before treatment, the medium in the bottom well was replaced with medium containing 100 mg/ml EGF. Twenty-four hours after treatment, membranes were fixed and processed according to manufacturer instructions. To calculate relative invasion, five arbitrary fields were counted/membrane, and the number of invading cells in the treated inserts was divided by the number of invading cells in the untreated (control) inserts.
Western blotting and immunofluorescence
Whole-cell extracts were isolated using 2X SDS lysis buffer (125 mM TrisHCl, 20% glycerol, 4% SDS) and quantified using the Pierce BCA Assay before addition of 10% b-mercaptoethanol. Lysates were analyzed by SDS À polyacrylamide gel electrophoresis and immunoblotting. Antibodies against phophorylated-ErbB2 (Y877), ErbB2, EGFR, phosphorylated Src (Y416), Src, phosphorylated Akt (S473), Akt and MMP2 were obtained from Cell Signaling (Danvers, MA, USA). Antibodies against phosphorylated Erk 1/2 (T185/Y187) and total Erk were obtained from Invitrogen and Promega (Madison, WI, USA), respectively. Antibodies against actin and nucleolin were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies against FoxM1 were obtained from Santa Cruz Biotechnology and Abcam (Cambridge, MA, USA). Detection of primary antibodies used either LICOR infrared secondary antibodies and visualization with the LICOR Odyssey Imager or horseradish peroxidase À conjugated secondary antibodies and chemiluminescence/autoradiography. Analysis of 3D structures via immunofluorescence was performed as previously described. 25 Primary antibodies against integrin a5 and integrin a6 were obtained from Millipore (Billerica, MA, USA). Laminin V antibody was obtained from Abcam. Alexa-488 and Alexa-568 secondary antibodies, as well as phalloidin were obtained from Invitrogen.
Quantitative real-time À PCR Total RNA was isolated from cells using the QIAGEN RNEasy Kit (Hilden, Germany), according to manufacturer's instructions. Two hundred and fifty nanogram total RNA was added to Stratagene Brilliant II quantitative real time À PCR master mix with primer/probe sets from Applied Biosystems (PP1A: Hs99999904_m1; MMP2: Hs00234422_m1; FOXM1: Hs01073586_m1; cyclophillin A: Hs99999904_m1; LDHA: Hs00855332_g1. All reactions were performed in technical duplicate with RNA from three independent experiments.
Statistics
All results are presented as mean ± s.e.m. and P-values calculated using Student's t-test.
